Park Avenue Securities LLC Decreases Stock Holdings in Sanofi (NASDAQ:SNY)

Park Avenue Securities LLC cut its holdings in Sanofi (NASDAQ:SNY - Free Report) by 19.5% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 55,543 shares of the company's stock after selling 13,439 shares during the period. Park Avenue Securities LLC's holdings in Sanofi were worth $3,080,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently bought and sold shares of the company. McClarren Financial Advisors Inc. boosted its holdings in Sanofi by 952.6% in the 4th quarter. McClarren Financial Advisors Inc. now owns 600 shares of the company's stock valued at $28,000 after purchasing an additional 543 shares during the period. Bessemer Group Inc. boosted its holdings in Sanofi by 59.8% in the 4th quarter. Bessemer Group Inc. now owns 647 shares of the company's stock valued at $32,000 after purchasing an additional 242 shares during the period. Lee Danner & Bass Inc. bought a new position in Sanofi in the 4th quarter valued at $31,000. Sierra Ocean LLC bought a new position in Sanofi in the 4th quarter valued at $44,000. Finally, UMB Bank n.a. boosted its holdings in Sanofi by 30.7% in the 1st quarter. UMB Bank n.a. now owns 1,124 shares of the company's stock valued at $62,000 after purchasing an additional 264 shares during the period. 14.04% of the stock is owned by institutional investors.

Sanofi Trading Down 2.3%

Sanofi stock traded down $1.16 during mid-day trading on Friday, hitting $49.67. The company's stock had a trading volume of 2,303,891 shares, compared to its average volume of 2,387,537. The company has a debt-to-equity ratio of 0.15, a current ratio of 1.46 and a quick ratio of 1.14. The stock has a market cap of $121.81 billion, a price-to-earnings ratio of 19.95, a price-to-earnings-growth ratio of 1.01 and a beta of 0.50. The business has a 50 day moving average price of $51.49 and a 200-day moving average price of $52.00. Sanofi has a 12 month low of $45.80 and a 12 month high of $60.12.

Sanofi (NASDAQ:SNY - Get Free Report) last posted its quarterly earnings results on Thursday, April 24th. The company reported $0.94 earnings per share for the quarter, topping the consensus estimate of $0.90 by $0.04. The business had revenue of $10.41 billion during the quarter, compared to the consensus estimate of $9.79 billion. Sanofi had a net margin of 12.77% and a return on equity of 25.61%. The firm's revenue for the quarter was down 11.0% on a year-over-year basis. During the same period in the previous year, the firm posted $1.78 earnings per share. As a group, analysts forecast that Sanofi will post 4.36 EPS for the current year.

Sanofi Increases Dividend

The firm also recently declared an annual dividend, which was paid on Thursday, June 12th. Shareholders of record on Friday, May 9th were paid a $2.0369 dividend. The ex-dividend date of this dividend was Friday, May 9th. This is an increase from Sanofi's previous annual dividend of $1.48. This represents a yield of 3.1%. Sanofi's payout ratio is currently 57.14%.

Analyst Ratings Changes

A number of analysts have recently issued reports on the stock. The Goldman Sachs Group assumed coverage on shares of Sanofi in a report on Friday, March 21st. They set a "neutral" rating and a $65.00 price objective for the company. Guggenheim reaffirmed a "buy" rating on shares of Sanofi in a report on Tuesday, June 3rd. BNP Paribas assumed coverage on shares of Sanofi in a report on Tuesday, April 15th. They set an "outperform" rating and a $65.00 price objective for the company. Hsbc Global Res raised shares of Sanofi to a "strong-buy" rating in a report on Monday, April 28th. Finally, Morgan Stanley set a $56.00 price objective on shares of Sanofi in a report on Monday, June 2nd. Three investment analysts have rated the stock with a hold rating, three have given a buy rating and three have assigned a strong buy rating to the company. Based on data from MarketBeat, Sanofi presently has a consensus rating of "Buy" and an average price target of $61.50.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.